Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

PURPOSE: To estimate the maximum-tolerated dose (MTD), describe dose-limiting toxicities (DLTs), and characterize pharmacokinetic properties of MK-0752, a gamma secretase inhibitor, in children with refractory or recurrent CNS malignancies. PATIENTS AND METHODS: MK-0752 was administered once daily f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fouladi, Maryam, Stewart, Clinton F., Olson, James, Wagner, Lars M., Onar-Thomas, Arzu, Kocak, Mehmet, Packer, Roger J., Goldman, Stewart, Gururangan, Sridharan, Gajjar, Amar, Demuth, Tim, Kun, Larry E., Boyett, James M., Gilbertson, Richard J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3179253/
https://ncbi.nlm.nih.gov/pubmed/21825264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.7806
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars